Molecular Pharmacology Program
The David Scheinberg Lab
Research
The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013).
Research Projects
Featured News
Publications
People
David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery
- Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine
- scheinbd@mskcc.org
- Email Address
- 646-888-2190
- Office Phone
- View physician profile
- Physician profile
Members
- Ph.D in Immunology from Hyogo College of Medicine, Japan (1990)
- MD in Medicine from Medical School of Inner Mongolia (1982)
- Postdoctoral from Yale Medical School Immunobiology (1999).
- PhD in Chemistry from Case Western Reserve University in Cleveland, Ohio (1985)
- ME in Chemical Engineering from The City University of New York (2004)
- BS in Biophysics from Humboldt University in Berlin (2018)
- MS in Biomedical Sciences from UCL London (2019)
- BA in Biology from Swarthmore College, Swarthmore, PA (2017)
- PhD in Oncology from A. C. Camargo Hospital, Sao Paulo, BR
- and from MD Anderson Cancer Center, Texas US (2009)
- MD, Weill Cornell Medicine College, (2015)
- BA Neuroscience, The Johns Hopkins University, (2007)
- BS in Pharmacology, MA in Molecular Biology, University of California, Santa Barbara
- MD from University of Central Florida College of Medicine, 2016
- PhD in Immunology from Heinrich Heine University, Germany (2015)
- BS in Biology from St. John' s University in Queens, NY (2017)
- MD in Internal Medicine from Sechenov (1st) Moscow Medical Institute, Moscow, Russia,(1990)
- PhD in Medical Science, from State Scientific Center of Russian Federation Institute of Biophysics, Moscow, Russia,(1997)
- BS in Biomedical Engineering from UC San Diego, CA (2012)
- MEng. in Biomedical Engineering from Cornell University (2013)
- BS in Chemistry from The College of New Jersey, Ewing NJ (2019)
- BS, Cornell University
- BS in Biomedical Engineering from Boston University (2016)
- MD from Eberhard Karls University in Tuebingen, Germany (2014)
- PhD in Chemistry from Tufts University (2018)
- BS in Biochemistry from Hobart and William Smith Colleges (2013)
Lab Alumni
Lab Affiliations
- Molecular Pharmacology Program
- Department of Medicine
- Center for Experimental Therapeutics
- Center for Cell Engineering
- Geoffrey Beene Cancer Research Center
- Center for Molecular Imaging & Nanotechnology
- Tri-Institutional PhD Program in Chemical Biology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Lab News & Events
Journal Club & Photo AlbumGet in Touch
-
Lab Head Email
-
Office Phone
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David A. Scheinberg discloses the following relationships and financial interests:
-
Actinium
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services -
Arvinas, Inc
Ownership / Equity Interests -
Bridge Medicines
Provision of Services (uncompensated) -
ContraFect
Ownership / Equity Interests -
Ensysce Bioscience
Ownership / Equity Interests -
Eureka Therapeutics Inc
Ownership / Equity Interests; Provision of Services (uncompensated) -
Great Point Partners
Ownership / Equity Interests; Provision of Services
-
Iovance Biotherapeutics, Inc.
Ownership / Equity Interests -
Lantheus Medical Imaging, Inc.
Ownership / Equity Interests -
OncoPep, Inc.
Provision of Services -
Pfizer, Inc.
Ownership / Equity Interests; Provision of Services -
Repertoire Immune Medicines, Inc.
Provision of Services -
Sapience Therapeutics, Inc.
Fiduciary Role/Position; Ownership / Equity Interests -
Sellas Life Science Group
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.